MAPS is a nonprofit organization that conducts research and education on psychedelics.

MAPS

Valis Bioscience focuses on improving the measurement and treatment of psychiatric and neurological disorders. The company specializes in psychedelic trials and rare and orphan disorders, developing tools for clinical trials and digital therapeutics.

Valis Bioscience

Psychedelic Science

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

We further our mission by:

● Developing psychedelics and marijuana into prescription medicines
● Training therapists and working to establish a network of treatment centers
● Supporting scientific research into spirituality, creativity, and neuroscience
● Educating the public honestly about the risks and benefits of psychedelics and marijuana

Multidisciplinary Association for Psychedelic Studies (MAPS)

Join MAPS at SXSW as we explore how breakthrough research and a growing business environment will impact the future applications of novel and traditional substances.

Swipe to see presentations featuring Rick Doblin, Ph.D., and Julie Holland, MD, that you won't want to miss! 💫

MAPS Welcomes New Investors and a Name Change for MAPS PBC, now Lykos.

A decade after it was founded as a wholly owned subsidiary of MAPS, MAPS Public Benefit Corporation (MAPS PBC) has announced the successful close of an oversubscribed Series A financing of more than $100 million, led by Helena, alongside a name change to Lykos Therapeutics and new visual identity.

https://lnkd.in/gbimDEqF

We're Backkkkkk ✨ 

🌟 Save the Date! 🌟 Join us in Denver, Colorado, from June 16–20, 2025, for the 5th edition of the Psychedelic Science conference! ✨ MAPS is thrilled to return to The Mile High City for another incredible week of learning and connection. 

Psychedelic Science covers the full spectrum of psychedelics, including science, medicine, policy, business, spirituality, and culture. It is welcoming to all community members, whether you are newly curious or decades into your journey.🎉

Don't miss out - mark your calendars now!

Sign up for the Psychedelic Science mailing list to be the first to know as details are released and registration opens.

https://lnkd.in/ewq5uPxP

Metric
Company Name	MAPS	Valis Bioscience
Symbol
MSH ID	ORG:MAPS	COM:VALISBIOSCIENCE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Mental Health Research and Education	Clinical Research
Country	US	US
Stage	Funding Round
Employee Count	128
Website	maps.org	valisbioscience.com
LinkedIn	mapsnews	valisbioscience
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	56.77K
Web Traffic Growth	-0.53
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MAPS

ORG:MAPS

MAPS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue